- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01203800
Evaluation of Blood Brain Barrier Permeability in Chronic Stroke
Study Overview
Status
Conditions
Detailed Description
Evaluation of Blood Brain Barrier Permeability in Chronic Stroke
Mordechai Lorberboym, M.D.1, Yair Lampl, M.D.2, Ronit Gilad, M.D.2.
From the Department of Nuclear Medicine1 and the department of Neurology2 of the Edith Wolfson Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Introduction
The blood brain barrier (BBB) is a highly selective barrier of brain microvascular endothelial cells that shields the brain from toxic substances in the blood, supplies brain tissues with nutrients, and filters harmful compounds from the brain back to the bloodstream (1). Transport across the BBB is strictly limited through both physical (tight junctions) and metabolic barriers (enzymes, diverse transport systems). BBB breakdown or alterations in transport systems play an important role in the pathogenesis of many CNS diseases (HIV-1 encephalitis, Alzheimer's disease, ischemia, tumors, multiple sclerosis, and Parkinson's disease).
Cerebral ischemia leads to disruption of blood flow, increased BBB permeability, and is associated with rapid depletion of essential nutrients and oxygen (2-3). Only a few studies were designed in humans in order to compare the degree of BBB changes and the neurological outcome after a stroke. The most significant stage of BBB breakdown occurs in humans within 48-72 hours post infarction and is accompanied by increased brain edema volume.
The investigators performed a study on thirty patients with acute stroke of the middle cerebral artery using technetium-99m-DTPA brain SPECT (4). Tc-99m-DTPA (Diethylenetriamine- pentacetic acid) brain scintigraphy is a useful technique for the assessment of BBB disruption. Is has been used in the past to localize areas within the cranium which had been disrupted by infection, neoplasms, trauma or stroke. The study showed that the magnitude of disruption of the BBB was negatively correlated with the change in neurological status with a sensitivity of 95% and a specificity of 89%. Interestingly, a significant proportion of patients with stroke (23%) had no gross evidence of BBB disruption, all of them with very good prognosis.
It is unclear for how long the BBB remains disrupted after a stroke, and whether there is any correlation between the BBB permeability and recurrent ischemic events or delayed functional and neurological outcome after a stroke.
Aim of the study
In this study the investigators intend to explore the long term significance of BBB disruption on the clinical course and the rate of significant recurrent ischemic events in patients with a chronic stroke.
Patients and methods Inclusion criteria
Male and female patients at any age with a history of a large stroke in the territory of the middle cerebral artery, occurring 1-2 years ago or between 2-5 years ago.
Exlusion criteria
Methods:
40 patients will be recruited from the Neurological Outpatient Clinic of the Edith Wolfson Medical Center and from the Neurological Department.
For the SPECT study each patient will receive 740 MBq Tc-99m-DTPA and a SPECT study will be performed 60-90- minutes later. A dual head or a triple head gamma camera is usually used, equipped with high resolution collimators.
References
- Persidsky Y, Ramirez SH, Haorah J, Kanmogne GD. Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J Neuroimmune Pharmacol 2006;1:223-236.
- del Zoppo GJ, Hallenbeck JM (2000) Advances in the vascular pathophysiology of ischemic stroke. Thromb Res 98:73-81
- Petty MA, Wettstein JG (2001) Elements of cerebral microvascular ischaemia. Brain Res Rev 36:23-34
- Lorberboym M, Lampl Y, Sadeh M. Correlation of 99mTc-DTPA SPECT of the blood-brain barrier with neurologic outcome after acute stroke. J Nucl Med 2003;44:1898-1904.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Holon, Israel, 58100
- Wolfson medical center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Male and female patients at any age with a history of a large stroke in the territory of the middle cerebral artery, occurring 1-2 years ago or between 2-5 years ago.
Exclusion Criteria:
- Lacunar strokes,
- CNS lesions other than a stroke,
- unable to perform the study.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Blood Brain Barrier permeability
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 0056-09-WOMC
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on A Positive or a Negative Brain SPECT
-
UNICANCERARCAGY/ GINECO GROUP; SOLTI Breast Cancer Research GroupActive, not recruitingER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer | a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI StatusFrance
-
Sohail RaoRecruitingSpecimens Are to be Collected From Subjects Who Are Having or Have Had a Fluid or Tissue Removed, a Biopsy or a Blood or Bone Marrow DrawUnited States
-
Children's Mercy Hospital Kansas CityRecruitingConditions Requiring a Brain Magnetic Resonance Imaging, Head Computerized Tomography, or Head UltrasoundUnited States
-
Children's Mercy Hospital Kansas CityRecruitingConditions Requiring a Brain Magnetic Resonance Imaging, Head Computerized Tomography, or Head UltrasoundUnited States
-
Abramson Cancer Center of the University of PennsylvaniaCompletedA Healthcare Professional, a Patient or Caregiver in the Radiation Oncology Department at the University of PennsylvaniaUnited States
-
AZ-VUBUnknownCancers Harbouring an EGFR Mutation, (Excluding Non-squamous Non- Small Cell Lung Cancer, a Registered Indication), a HER2 Mutation or a HER3 MutationBelgium
-
UPECLIN HC FM Botucatu UnespCompletedInvestigation or Care in A Nonpregnant Woman | Mother (Person)Brazil
-
Abbott Medical DevicesCompletedPatients Requiring a Diagnostic and/or Interventional Diagnostic ProcedureGermany
-
Retropsoas Technologies, LLCNot yet recruitingUndergoing a Single-level or Two-level TLIF SurgeryUnited States
-
University Hospital, AkershusVestre Viken Hospital Trust; NovartisRecruitingBreast Cancer | Locally Advanced Breast Cancer | ER-positive Breast Cancer | HER2-negative Breast Cancer | Luminal A Breast Cancer | Luminal B Breast CancerNorway